Build payer access
Managed Medicare Part D, Medicaid MCO, commercial PBM, and PSAO relationships and network participation.
SELECTED WORK / 03 / Nova Q Health & Viva Pharmacy
Build the business behind the prescription.
Own the economics, staffing, payer access, compliance, technology, and patient-service model of a specialty-pharmacy platform—from formation through divestiture.
Co-Founder & Chief Operating Officer · 2019–2023
- annualized revenue
- $8M+
- EBITDA margin
- 18%+
- person team
- 25
THE CONSTRAINT
Can the platform scale access while preserving margin, quality, and transaction readiness?
Specialty-pharmacy growth depends on clinical access, reimbursement, purchasing, dispensing, documentation, and service reliability working together. Scaling one without the others can erode both margin and access.
Specialty-pharmacy operating model
A reconstructed leadership exhibit connecting payer access, fulfillment, patient service, and financial control.
- 01Payer access
- 02Therapy + authorization
- 03Inventory + dispensing
- 04Patient follow-through
- 05Margin + quality
Review conversion, access, economic value, and exceptions → adjust the next operating decision.
WHAT I BUILT
Own the operating model
Led P&L, staffing, purchasing, inventory, drug-mix strategy, reimbursement, and performance controls.
Automate with accountability
Introduced ScriptPro dispensing automation while strengthening quality and complex-therapy workflows.
Prepare for transition
Maintained compliance, documentation, data preparation, and diligence readiness for strategic divestiture to Rite Aid.
REPORTED OPERATING OUTCOMES
What changed.
- Scaled from $0 to $8M+ in annualized revenue.
- Reported 150% throughput improvement with 99.97% dispensing accuracy.
- Expanded complex-therapy access to 10,000 covered lives.
THE EXECUTIVE DECISION
Executive decision brief
CEO question
What system did this work make more launchable, fundable, or scalable?
Operating answer
The most transferable founder signal is not just that the business scaled. It is that reimbursement, compliance, operations, and buyer diligence became one system.
Proof to inspect
Founder build, margin discipline, URAC, ScriptPro automation, dispensing reliability, and a Rite Aid exit matter together because they show an end-to-end regulated asset: commercial demand, operational discipline, compliance readiness, and buyer credibility.
Scope & source
Annualized revenue is not described as subscription ARR. Operating results and divestiture scope are self-reported in the executive résumé; employer and counterparty names do not imply endorsement.
Read the source résumé